Origin

Origin, Inc. is a Phase III clinical-stage biotechnology company that applies its proprietary technology to generate and deliver nitric oxide (NO) from a defined high-energy plasma stream. The company recently completed a Phase IIb dose-ranging trial for the treatment of chronic diabetic foot ulcers. Origin’s unique plasma stream delivers therapeutic concentrations of NO directly to the target area without stimulating any activity beneath the skin. NO is a bioactive substance that alters disease pathways through antimicrobial, anti-inflammatory, tissue regeneration, and vasodilation activities. Origin's technology is currently under investigation for several highly unmet medical conditions, including the treatment of wounds, ulcers, and acute and chronic infections. The planned expanded clinical pipeline includes potential indications in dermatology, dentistry, pain, and inflammation. Origin, Inc. was founded in 2010 and is headquartered in Princeton, New Jersey.